I-MABIMAB
Market Cap: $86.1M
About: I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Employees: 220
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
67% more call options, than puts
Call options by funds: $5K | Put options by funds: $3K
13% more capital invested
Capital invested by funds: $22.4M [Q1] → $25.3M (+$2.9M) [Q2]
1.86% more ownership
Funds ownership: 6.28% [Q1] → 8.14% (+1.86%) [Q2]
3% less funds holding
Funds holding: 38 [Q1] → 37 (-1) [Q2]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
78% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 18
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 167 met price target | 621%upside $8 | Buy Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 167 met price target | 621%upside $8 | Buy Reiterated | 29 Aug 2024 |
Financial journalist opinion
Based on 5 articles about IMAB published over the past 30 days